Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909500 | 0.87 | LMNA (0.44) | ELANEBACE1 | |
| SCHEMBL18613360 | 0.82 | KMT2A (0.49) | ELANEBACE1DRD2 | |
| SCHEMBL28711315 | 0.82 | ELANE (0.41) | ELANEBACE1PRSS1TMPRSS15 | |
| SCHEMBL20168323 | 0.79 | ELANE (0.56) | ELANEALOX15HTR2APTGS2 | |
| SCHEMBL32673207 | 0.78 | BACE1 (0.40) | ELANEBTN3A1BACE1 | |
| SCHEMBL16610043 | 0.78 | MAPT (0.55) | ELANEL3MBTL1 | |
| SCHEMBL18613361 | 0.78 | KMT2A (0.44) | ELANEL3MBTL1 | |
| SCHEMBL16610054 | 0.77 | SMN1; SMN2 (0.51) | PRSS1 | |
| SCHEMBL18020584 | 0.77 | PRSS1 (0.46) | ATML3MBTL1PRSS1 | |
| SCHEMBL2882196 | 0.75 | PTGS2 (0.51) | HTR2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096092-A1 | THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | HEALTH AND HUMAN SERVICES (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096092-A1 | THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | SLC30A7, SLC30A6, SLC39A7 | ELANE 1818/4885ALOX15 2617/4885HTR2A 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.